Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey

Ergör, Gül; DİNÇ HORASAN, Gönül; KESKİNKILIÇ, Bekir; SAKARYA, SİBEL; SÖZMEN, Kaan; ÜNAL, Belgin; Yardim, Nazan

Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey

Kaan SÖZMEN, (Department of Public Health, Faculty of Medicine, Katip Çelebi University; İzmir, Turkey;)

Belgin ÜNAL, (Department of Biostatistics and Medical Informatics, Faculty of Medicine, Celal Bayar University; Manisa, Turkey;)

Sibel SAKARYA, (Department of Public Health, Faculty of Medicine, Marmara University; İstanbul, Turkey)

Gönül DİNÇ HORASAN, (Department of Biostatistics and Medical Informatics, Faculty of Medicine, Celal Bayar University; Manisa, Turkey)

Nazan YARDIM, (Department of Obesity, Diabetes,Metabolic Diseases, Turkish Institute of Public Health, Ministry of Health; Ankara, Turkey)

Bekir KESKİNKILIÇ, (Department of Chronic Diseases, Elderly Health and Disabled, Turkish Institute of Public Health, Ministry of Health; Ankara-Turkey)

Gül ERGÖR (Department of Public Health, Faculty of Medicine,Dokuz Eylül University; İzmir, Turkey)

The Anatolian Journal of Cardiology

0 0

Yıl: 2016 Cilt: 16 Sayı: 6 Sayfa Aralığı: 370 - 384 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey

Öz:

Objective: High blood cholesterol is one of the main modifiable risk factors for cardiovascular diseases (CVDs). The aim of the study is to determine the factors associated with the prevalence, awareness, treatment, and control of high "low-density lipoprotein-cholesterol" (LDL-C) among adults aged >=20 years in Turkey.Methods: We used data from Chronic Diseases and Risk Factors Survey conducted in 2011-2012. The presence of high LDL-C, lipid-lowering treatment eligibility, and achievement of target LDL-C were defined according to the third Adult Treatment Panel guidelines on treatment of high cholesterol. Multivariate logistic regression analyses were performed to determine the associations between participant characteristics and high LDL-C prevalence, awareness, treatment, and control.Results: Framingham risk score categorization was performed for 13121 individuals aged >=20 years. Approximately, 28% of the participants presented with high LDL-C. Among those with high LDL-C, 55.8% were aware of their situation; among those aware of high LDL-C, 46.9% were receiving lipidlowering medication, and 50.6% of individuals who were receiving treatment achieved target LDL-C levels on the basis of their coronary heart disease (CHD) risk. Control of high LDL-C was negatively associated with the presence of diabetes mellitus (odds ratio: 0.36, 95% CI: 0.27-0.49, p<0.001).Conclusion: Despite the high awareness rates, there was a high proportion of adults who did not receive treatment or achieve recommended levels of LDL-C during treatment. The low treatment and control levels among individuals based on their CHD risk levels call for a better application of recommendations regarding personal preventive measures and treatments in Turkey.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. WHO. Global Atlas on Cardiovascular Disease Prevention and Control World Health Organization, 2011.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repre sentatives of nine societies and by invited experts). Atherosclerosis 2012; 223: 1-68.
4. Dinç G, Sözmen K, Gerçeklioğlu G, Arık H, Critchley J, Unal B. Decreasing trends in cardiovascular mortality in Turkey between 1988 and 2008. BMC Public Health 2013; 13: 896.
5. Ünal B, Sözmen K, Arık H, Gerçeklioğlu G, Altun DU, Şimşek H, et al. Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008. BMC Public Health 2013; 13: 1135.
6. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011; 377: 578-86.
7. Ünal B, Sözmen K, Uçku R, Ergör G, Soysal A, Baydur H, et al. High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anatol J Cardiol 2013; 13: 9-17.
8. Onat A. Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease. Anatol J Cardiol 2004; 4: 236- 45.
9. Erem C, Hacıhasanoğlu A, Değer O, Koçak M, Topbaş M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008; 34: 36-51.
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149-61.
11. Firmann M, Marques-Vidal P, Paccaud F, Mooser V, Rodondi N, Waeber G, et al. Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. Eur J Cardiovasc Prev Rehabil 2010; 17: 682-7.
12. Rodriguez CJ, Cai J, Swett K, Gonzalez HM, Talavera GA, Wruck LM, et al. High Cholesterol Awareness, Treatment, and Control Among Hispanic/Latinos: Results From the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc 2015; 4.
13. Shirani S, Kelishadi R, Sarrafzadegan N, Khosravi A, Sadri G, Amani A, et al. Awareness, treatment and control of hypertension, dyslipidaemia and diabetes mellitus in an Iranian population: the IHHP study. East Mediterr Health J 2009; 15: 1455-63.
14. MOH. Chronic Diseases and Risk Factors Survey in Turkey. Ankara: Republic of Turkey Ministry of Health 2013.
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
16. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-95.
17. Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 2005; 25: 2243-4.
18. American Diabetes A. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes 2015; 33: 97-111.
19. Bayram F, Koçer D, Gündoğan K, Kaya A, Demir O, Çoşkun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol 2014; 8: 206-16.
20. Mahley RW, Palaoglu KE, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36: 839-59.
21. Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PloS one 2014; 9: e96808.
22. Pongchaiyakul C, Nguyen TV, Kosulwat V, Rojroongwasinkul N, Charoenkiatkul S, Pongchaiyakul C, et al. Defining obesity by body mass index in the Thai population: an epidemiologic study. Asia Pac J Clin Nutr 2006; 15: 293-9.
23. MOH. National Turkey Nutrition and Health Survey (TNHS) - 2010. Ankara: Sağlık Araştırmaları Genel Müdürlüğü, 2014.
24. Flannery C, Dufour S, Rabol R, Shulman GI, Petersen KF. Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 2012; 61: 2711-7.
25. Ni WQ, Liu XL, Zhuo ZP, Yuan XL, Song JP, Chi HS, et al. Serum lipids and associated factors of dyslipidemia in the adult population in Shenzhen. Lipids Health Dis 2015; 14: 71.
26. Gallo LC, Troxel WM, Kuller LH, Sutton-Tyrrell K, Edmundowicz D, Matthews KA. Marital status, marital quality, and atherosclerotic burden in postmenopausal women. Psychosom Med 2003; 65: 952- 62.
27. Lorenz FO, Wickrama KA, Conger RD, Elder GH, Jr. The short-term and decade-long effects of divorce on women's midlife health. J Health Soc Behav 2006; 47: 111-25.
28. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: A systematic review and metaanalysis. JAMA 2007; 298: 2654-64.
29. He H, Yu YQ, Li Y, Kou CG, Li B, Tao YC, et al. Dyslipidemia awareness, treatment, control and influence factors among adults in the Jilin province in China: a cross-sectional study. Lipids Health Dis 2014; 13: 122.
30. Muntner P, Levitan EB, Brown TM, Sharma P, Zhao H, Bittner V, et al. Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol 2013;112:664-70.
31. Aekplakorn W, Taneepanichskul S, Kessomboon P, Chongsuvivatwong V, Putwatana P, Sritara P, et al. Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009. J Lipids 2014; 2014: 249584.
32. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009; 64: 256-63.
33. Awad A, Al-Nafisi H. Public knowledge of cardiovascular disease and its risk factors in Kuwait: a cross-sectional survey. BMC Public Health 2014; 14: 1131.
34. Cheng S, Lichtman JH, Amatruda JM, Smith GL, Mattera JA, Roumanis SA, et al. Knowledge of cholesterol levels and targets in patients with coronary artery disease. Prev Cardiol 2005; 8: 11-7.
35. Sözmen K, Ünal B. Explaining inequalities in Health Care Utilization among Turkish adults: Findings from Health Survey 2008. Health Policy 2016; 120: 100-10.
36. Satman I, Ömer B, Tütüncü Y, Kalaca S, Gedik S, Dincçağ N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28: 169-80.
37. Brown TM, Tanner RM, Carson AP, Yun H, Rosenson RS, Farkouh ME, et al. Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. Diabetes Care 2013; 36: 2734-40.
38. Scranton RE, Farwell WR, Gaziano JM. Lack of cholesterol awareness among physicians who smoke. Int J Environ Res Public Health 2009; 6: 635-42.
39. MacDonald TM, M orant SV. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol 2008; 65: 775-86.
40. Lee YH, Lee SG, Lee MH, Kim JH, Lee BW, Kang ES, et al. Serum cholesterol concentration and prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in the Korea National Health and Nutrition Examination Surveys 2008-2010: Beyond the Tip of the Iceberg. J Am Heart Assoc 2014; 3: 446.
41. Vital signs: prevalence, treatment, and control of high levels of lowdensity lipoprotein cholesterol--United States, 1999-2002 and 2005- 2008. MMWR Morb Mortal Wkly Rep 2011; 60: 109-14.
42. Tolonen H, Keil U, Ferrario M, Evans A, Project WM. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol 2005; 34: 181-92.
43. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and metaanalysis. Ann Pharmacother 2010; 44: 1410-21.
44. Merkin SS, Karlamangla A, Crimmins E, Charette SL, Hayward M, Kim JK, et al. Education differentials by race and ethnicity in the diagnosis and management of hypercholesterolemia: a national sample of U.S. adults (NHANES 1999-2002). Int J Public Health 2009; 54: 166-74.
45. Khoo CM, Tan ML, Wu Y, Wai DC, Subramaniam T, Tai ES, et al. Prevalence and control of hypercholesterolaemia as defined by NCEP-ATPIII guidelines and predictors of LDL-C goal attainment in a multi-ethnic Asian population. Ann Acad Med Singap 2013; 42: 379-87.
46. Hyre AD, Muntner P, Menke A, Raggi P, He J. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007; 17: 548-55.
47. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005; 82: 222S-5S.
48. Yiğiner Ö, Özmen N, Özçelik F, İnanç T, Kardeşoğlu E, Uz Ö, et al. Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: the role of education and knowledge. Turk Kardiyol Derg Ars 2010; 38: 544-50.

APA	SÖZMEN K, ÜNAL B, SAKARYA S, DİNÇ HORASAN G, Yardim N, KESKİNKILIÇ B, Ergör G (2016). Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. , 370 - 384.
Chicago	SÖZMEN Kaan,ÜNAL Belgin,SAKARYA SİBEL,DİNÇ HORASAN Gönül,Yardim Nazan,KESKİNKILIÇ Bekir,Ergör Gül Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. (2016): 370 - 384.
MLA	SÖZMEN Kaan,ÜNAL Belgin,SAKARYA SİBEL,DİNÇ HORASAN Gönül,Yardim Nazan,KESKİNKILIÇ Bekir,Ergör Gül Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. , 2016, ss.370 - 384.
AMA	SÖZMEN K,ÜNAL B,SAKARYA S,DİNÇ HORASAN G,Yardim N,KESKİNKILIÇ B,Ergör G Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. . 2016; 370 - 384.
Vancouver	SÖZMEN K,ÜNAL B,SAKARYA S,DİNÇ HORASAN G,Yardim N,KESKİNKILIÇ B,Ergör G Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. . 2016; 370 - 384.
IEEE	SÖZMEN K,ÜNAL B,SAKARYA S,DİNÇ HORASAN G,Yardim N,KESKİNKILIÇ B,Ergör G "Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey." , ss.370 - 384, 2016.
ISNAD	SÖZMEN, Kaan vd. "Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey". (2016), 370-384.

APA	SÖZMEN K, ÜNAL B, SAKARYA S, DİNÇ HORASAN G, Yardim N, KESKİNKILIÇ B, Ergör G (2016). Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. The Anatolian Journal of Cardiology, 16(6), 370 - 384.
Chicago	SÖZMEN Kaan,ÜNAL Belgin,SAKARYA SİBEL,DİNÇ HORASAN Gönül,Yardim Nazan,KESKİNKILIÇ Bekir,Ergör Gül Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. The Anatolian Journal of Cardiology 16, no.6 (2016): 370 - 384.
MLA	SÖZMEN Kaan,ÜNAL Belgin,SAKARYA SİBEL,DİNÇ HORASAN Gönül,Yardim Nazan,KESKİNKILIÇ Bekir,Ergör Gül Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. The Anatolian Journal of Cardiology, vol.16, no.6, 2016, ss.370 - 384.
AMA	SÖZMEN K,ÜNAL B,SAKARYA S,DİNÇ HORASAN G,Yardim N,KESKİNKILIÇ B,Ergör G Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. The Anatolian Journal of Cardiology. 2016; 16(6): 370 - 384.
Vancouver	SÖZMEN K,ÜNAL B,SAKARYA S,DİNÇ HORASAN G,Yardim N,KESKİNKILIÇ B,Ergör G Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. The Anatolian Journal of Cardiology. 2016; 16(6): 370 - 384.
IEEE	SÖZMEN K,ÜNAL B,SAKARYA S,DİNÇ HORASAN G,Yardim N,KESKİNKILIÇ B,Ergör G "Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey." The Anatolian Journal of Cardiology, 16, ss.370 - 384, 2016.
ISNAD	SÖZMEN, Kaan vd. "Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey". The Anatolian Journal of Cardiology 16/6 (2016), 370-384.